Menu Back toLS28: Issues in Handling of Cartagena Type 1 Use Regulations for Simultaneous International Development of Gene Therapy Drugs

18th DIA Japan Annual Meeting 2021

All prices are exclusive of 10% Japanese consumption tax

LS28: Issues in Handling of Cartagena Type 1 Use Regulations for Simultaneous International Development of Gene Therapy Drugs

Session Chair(s)

Masafumi  Onodera, MD, PhD

Masafumi Onodera, MD, PhD

  • Director, Center of Gene Cell Therapy Promotion,
  • National Center for Child Health and Development, Japan

Speaker(s)

Toshiyuki  Nagao

Toshiyuki Nagao

  • Director, Regulatory Affairs Area, Japan Development
  • MSD K.K., Japan
Akira  Sakurai, PhD

Akira Sakurai, PhD

  • Senior scientist for biopharmaceutical quality
  • Pharmaceuticals and Medical Devices Agency (PMDA), Japan

Contact us